Product

LGM-2605

The Problem

Pulmonary Fibrosis is a progressive deadly disease that kills 40,000 people annually

50,000 new cases diagnosed per year, median survival is 3-5 years

Two treatments available to slow disease progression but with significant side effects

Many patients go onto requiring a lung transplant, which has poor survival rates

There exists a clear need for new therapies to treat Pulmonary Fibrosis

The Solution LGM2605

Novel small molecule, once-a-day oral treatment

Reverses progression of the disease without serious side effects

Unique three-prong mechanism of action

Can be used alone or in combination with existing therapies

Indications:
  • Treatment of Pulmonary Fibrosis
  • Treatment of Pneumonitis
Outcomes:
  • Stop/reverse disease progression
  • Improve Pulmonary Fibrosis patient mobility/quality of life
  • Reduce cost of Pulmonary Fibrosis therapy
  • Reduce overall Healthcare Costs
Other opportunities:
  • Device to increase the number & quality of donor lungs available for transplant
  • Therapy to prevent ischemia reperfusion injury in lung transplant recipients
  • Supportive care to prevent lung damage during radiation treatment of thoracic cancers
  • Mitigation agent to treat radiation lung damage from nuclear accident or attack
    (Contract awarded by NIAID to support development activities required for FDA approval under the Animal Rule. If the development program is successful, LGM2605 will be a candidate for procurement for the U.S. Strategic National Stockpile.)